indications for glp-1 agonists Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus GLP-1 agonists for weight loss:

Clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: real-world study

Slower gastric emptying may alter absorption

Reid J, Rana K, Segel SA, Sheikh-Ali M, Choksi RR, Goldfaden RF

Clinically significant RGC, assessed by gastric ultrasound, is defined as a volume greater than 1.5 mL kg 2 [4, 5]

3.1.2 Exenatide As the first GLP-1R agonist approved for T2DM, EX is a new class of compound and a synthetic product of exendin-4, which is a compound naturally derived from the Gila monster and has multiple hypoglycemic mechanisms: inhibiting of glucagon release from cells, slowing of gastric emptying, decreasing appetite and increasing glucose-dependent insulin secretion (12, 46, 47)

Rev Endocr Metab Disord 15(3):181187 Shan Y, Tan S, Lin Y, Liao S, Zhang B, Chen X et al (2019) The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke